This is a preprint.
Structural basis of RNA-guided transcription by a dCas12f-σE-RNAP complex
- PMID: 40661421
- PMCID: PMC12259091
- DOI: 10.1101/2025.06.10.658880
Structural basis of RNA-guided transcription by a dCas12f-σE-RNAP complex
Abstract
RNA-guided proteins have emerged as critical transcriptional regulators in both natural and engineered biological systems by modulating RNA polymerase (RNAP) and its associated factors1-5. In bacteria, diverse clades of repurposed TnpB and CRISPR-associated proteins repress gene expression by blocking transcription initiation or elongation, enabling non-canonical modes of regulatory control and adaptive immunity1,6,7. Intriguingly, a distinct class of nuclease-dead Cas12f homologs (dCas12f) instead activates gene expression through its association with unique extracytoplasmic function sigma factors (σE)8, though the molecular basis has remained elusive. Here we reveal a novel mode of RNA-guided transcription initiation by determining cryo-electron microscopy structures of the dCas12f-σE system from Flagellimonas taeanensis. We captured multiple conformational and compositional states, including the DNA-bound dCas12f-σE-RNAP holoenzyme complex, revealing how RNA-guided DNA binding leads to σE-RNAP recruitment and nascent mRNA synthesis at a precisely defined distance downstream of the R-loop. Rather than following the classical paradigm of σE-dependent promoter recognition, these studies show that recognition of the -35 element is largely supplanted by CRISPR-Cas targeting, while the melted -10 element is stabilized through unusual stacking interactions rather than insertion into the typical recognition pocket. Collectively, this work provides high-resolution insights into an unexpected mechanism of RNA-guided transcription, expanding our understanding of bacterial gene regulation and opening new avenues for programmable transcriptional control.
Conflict of interest statement
COMPETING INTERESTS S.H.S. is a co-founder and scientific advisor to Dahlia Biosciences, a scientific advisor to CrisprBits and Prime Medicine, and an equity holder in Dahlia Biosciences and CrisprBits. S.H.S., F.T.H., and T.W. are inventors on patents related to CRISPR-Cas-like systems and uses thereof. The other authors declare no competing interests.
Figures
References
-
- Gilbert L. A., Horlbeck M. A., Adamson B., Villalta J. E., Chen Y., Whitehead E. H., Guimaraes C., Panning B., Ploegh H. L., Bassik M. C., Qi L. S., Kampmann M. & Weissman J. S. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 159, 647661, doi: 10.1016/j.cell.2014.09.029 (2014). - DOI - PMC - PubMed
-
- Zalatan J. G., Lee M. E., Almeida R., Gilbert L. A., Whitehead E. H., La Russa M., Tsai J. C., Weissman J. S., Dueber J. E., Qi L. S. & Lim W. A. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell 160, 339–350, doi: 10.1016/j.cell.2014.11.052 (2015). - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources